HoldsUp

Eran Elinav

Weizmann Institute of Science and German Cancer Research Center

Eran Elinav, MD, PhD, is a professor of immunology and principal investigator at the Weizmann Institute of Science and the German Cancer Research Center, where he co-directs the Personalized Nutrition Project. His research focuses on host-microbiome interactions and how gut bacteria impact human health and disease. His published work investigates topics including personalized nutrition, dietary assessment, mucosal immunity, metabolic disorders, and cancer-microbiome interactions.

53 claims checked on air: 2 context 6 overstated 42 supported 3 unverified

What they said on air - overstated

5 citing their own research

0:18:45overstatedlowDr. Eran Elinav on Microbiome Insights into Personalized Res

Indigenous hunter-gatherer populations can have a gut microbiome diversity that is tenfold higher than that of individuals living in modern industrialized societies.

"if you look at indigenous populations of humans, uh, hunter-gatherers and so on and so forth, you would find, um, in some studies that the diversity of the microbiome can be tenfold higher than the average diversity that we, um, can see and measure, um, in in the same human beings when they live in modern, quote-unquote, societies or industrialized societies." (said at 0:18:45)

Observational metagenomic studies comparing traditional hunter-gatherer and isolated indigenous populations (such as the Hadza of Tanzania and uncontacted Yanomami Amerindians) to urban industrialized cohorts show that indigenous populations harbor significantly higher microbial richness and alpha diversity. However, describing this difference as 'tenfold higher' (1000% higher) is a substantial overstatement. Comparative studies demonstrate modest increases (e.g., approximately 30–50% higher diversity metrics in isolated groups compared to Western urban controls), far below a 10-fold difference.

0:42:27overstatedhightheir own paperDr. Eran Elinav on Microbiome Insights into Personalized Res

Over 100,000 individuals have been tested on thousands of food components and food additives through the Personalized Nutrition pipeline.

"and we've tested thousands of them in in over 100,000 people that underwent our personalized nutrition uh pipeline or project—we found that people distinctly react to foods or food components or food additives, even if they're exposed to the same exact amounts of the same exact component." (said at 0:42:27)

Published peer-reviewed literature from the Personalized Nutrition Project supports the core premise that individuals demonstrate distinct, personalized glycemic and metabolic responses when exposed to identical foods or food additives (PMID: 26590418, PMID: 35987213). However, claiming that over 100,000 individuals were tested across thousands of food components within this research pipeline overstates the cohort sizes published in peer-reviewed studies. The primary study establishing the Personalized Nutrition Project evaluated continuously monitored glycemic responses to 46,898 meals in an 800-person cohort with an independent 100-person validation cohort (PMID: 26590418). Specific clinical trials investigating food additives (such as non-nutritive sweeteners) were conducted in cohorts of 120 participants (PMID: 35987213).

0:44:59overstatedmoderateDr. Eran Elinav on Microbiome Insights into Personalized Res

Up to 80% of obese individuals who lose weight regain all lost weight within 12 months.

"And this phenomenon, which is medically called recurrent obesity, but is more widely known as yo-yo obesity, characterizes up to 80% of all obese individuals worldwide... but then within 12 months of successfully dieting, 80% of people go on to redevelop obesity or regain all the weight that they've lost, and even regain a little bit more than they originally had." (said at 0:44:59)

The claim overstates the degree and rapidity of weight regain after dieting. The widely cited ~80% figure originates from epidemiological and registry definitions showing that approximately 20% of overweight individuals successfully maintain a weight loss of at least 10% of initial body weight for at least one year (meaning ~80% fail to maintain that specific long-term target). However, failing to maintain a 10% weight reduction is not equivalent to regaining 100% (or more) of lost weight within 12 months; structured weight-loss trials show that individuals typically retain a significant portion of weight loss at 12 months, with full regain occurring more gradually over 3 to 5 years.

1:12:05overstatedmoderateDr. Eran Elinav on Microbiome Insights into Personalized Res

Antibiotic administration clears the indigenous microbiome, permitting supplemental probiotics to colonize the gut in humans and mice.

"was that both in the human and the mouse setting, when you disrupt the indigenous microbiome by the administration of antibiotics, for example, you kind of empty out the neighborhood. And now you give probiotics, now the neighborhood is empty and the probiotics are no longer met by resistance, and now they can colonize the gut." (said at 1:12:05)

The claim overstates the effect in mice and implies a complete clearance ("emptying out") of the native flora. A study in human volunteers and mouse models (PMID 30193113) demonstrated that while antibiotic disruption enhanced mucosal probiotic colonization in humans compared to baseline homeostasis, it only mildly improved probiotic colonization in mice. Furthermore, antibiotics perturb rather than completely erase the native microbiota, and post-antibiotic probiotic administration markedly delayed the natural reconstitution of the indigenous human gut microbiome.

1:21:21overstatedhighDr. Eran Elinav on Microbiome Insights into Personalized Res

No probiotic preparation has been approved as a medical drug intervention by the FDA or the European Medicines Agency.

"And and the evidence is that not a single probiotic preparation to date has been approved as a medical intervention by the FDA or by the European counterparts of the FDA." (said at 1:21:21)

The speaker claims that no probiotic preparation has been approved as a medical intervention by the FDA or its European counterparts (such as the EMA). Regulatory bodies like the FDA classify medical live microorganism preparations under the regulatory framework of Live Biotherapeutic Products (LBPs) rather than under the traditional dietary supplement definition of "probiotic." However, the FDA has formally approved live microbial drug interventions to prevent recurrent *Clostridioides difficile* infection, such as Rebyota (fecal microbiota live-jslm) and Vowst (fecal microbiota spores live-brpk). While traditional dietary probiotic products sold over the counter lack FDA/EMA drug approval, the claim that no live bacterial/microbial therapeutic preparation has been approved as a medical drug intervention by the FDA is incorrect.

1:28:25overstatedhighDr. Eran Elinav on Microbiome Insights into Personalized Res

Antibiotic interventions increased human lifespan by close to 30 years within a century.

"You know, they increased, I think, close to 30 years of lifespan within a century, and and at least partially took care of what is considered to be our number one, two, and three cause of mortality for millions of years." (said at 1:28:25)

Total U.S. life expectancy increased by 29.2 years during the 20th century, driven largely by reductions in infectious disease mortality (pneumonia, tuberculosis, and diarrhea/enteritis were indeed the top three causes of death in 1900). However, attributing this full 30-year gain specifically to antibiotic interventions overstates their role. Antibiotics were not introduced into clinical use until the 1940s, whereas substantial declines in infectious mortality occurred earlier in the 20th century as a result of broad public health and environmental interventions, including clean water systems, improved sanitation, food safety, hygiene, and vaccination.

Fact-checked episodes

Publications